Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Overview of attention for article published in Lancet Oncology, October 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 4 news stories from 4 outlets.

/decade3d, stock.adobe.com Lugano/Kln Die derzeit wichtigste Treibermutation neben denen des EGF-Rezeptors beim nicht-kleinzellig…

By Matthew Stenger Posted: 11/6/2017 9:53:30 AM Last Updated: 11/6/2017 9:53:30 AM Tweet this page Advertisement Response to…

medwireNews: Approximately half of patients with anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 (ROS1) rearranged non-s…

In this phase 1, dose-escalation study, lorlatinib showed both systemic and intracranial activity in patients with advanced ALK-p…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.